Biological disease‐modifying drugs for rheumatoid arthritis
Prescriber2020Vol. 31(4), pp. 22–27
Citations Over Time
Abstract
There are now nine biological disease‐modifying antirheumatic drugs (bDMARDs) available for the treatment of rheumatoid arthritis – seven monoclonal antibodies and two fusion proteins. This article summarises their indications, efficacy, place in therapy and adverse effects.
Related Papers
- → Adverse reactions and safety of newer disease-modifying antirheumatic drugs (DMARDs) for rheumatoid arthritis(2007)1 cited
- → Biologic treatments for rheumatoid arthritis(2019)1 cited
- Biologic agents for rheumatoid arthritis treatment(2011)
- [The role of disease-modifying antirheumatic drugs (DMARDs) in the therapy of rheumatoid arthritis].(1993)
- → What is the effect of adding a disease-modifying antirheumatic drug (DMARD) to methotrexate (MTX) for people with rheumatoid arthritis and an inadequate response to MTX alone?(2020)